Strs Ohio Increases Holdings in Acelyrin, Inc. (NASDAQ:SLRN)

Strs Ohio increased its holdings in shares of Acelyrin, Inc. (NASDAQ:SLRN) by 504.3% in the 4th quarter, HoldingsChannel reports. The firm owned 42,300 shares of the company’s stock after acquiring an additional 35,300 shares during the quarter. Strs Ohio’s holdings in Acelyrin were worth $315,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently modified their holdings of SLRN. Walleye Capital LLC purchased a new position in shares of Acelyrin during the 3rd quarter valued at approximately $4,550,000. Rafferty Asset Management LLC purchased a new position in Acelyrin in the third quarter valued at $1,766,000. Vontobel Holding Ltd. purchased a new position in Acelyrin in the fourth quarter valued at $2,429,000. Barclays PLC acquired a new position in shares of Acelyrin in the third quarter worth about $1,084,000. Finally, Schonfeld Strategic Advisors LLC increased its stake in shares of Acelyrin by 267.1% in the 3rd quarter. Schonfeld Strategic Advisors LLC now owns 202,662 shares of the company’s stock valued at $2,061,000 after purchasing an additional 147,454 shares in the last quarter. Hedge funds and other institutional investors own 87.31% of the company’s stock.

Insider Buying and Selling at Acelyrin

In other news, CEO Shao-Lee Lin sold 15,701 shares of the company’s stock in a transaction that occurred on Tuesday, February 20th. The stock was sold at an average price of $7.60, for a total value of $119,327.60. Following the completion of the sale, the chief executive officer now directly owns 1,587,335 shares in the company, valued at $12,063,746. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Acelyrin Stock Performance

Shares of SLRN stock opened at $4.24 on Tuesday. Acelyrin, Inc. has a fifty-two week low of $4.18 and a fifty-two week high of $29.88. The stock’s fifty day moving average is $6.78 and its two-hundred day moving average is $7.54. The firm has a market capitalization of $419.39 million and a P/E ratio of -0.40.

Acelyrin (NASDAQ:SLRN) last issued its earnings results on Thursday, March 28th. The company reported ($0.75) EPS for the quarter, beating analysts’ consensus estimates of ($1.00) by $0.25. On average, equities analysts forecast that Acelyrin, Inc. will post -4.18 earnings per share for the current year.

Wall Street Analysts Forecast Growth

SLRN has been the topic of a number of recent analyst reports. Wells Fargo & Company increased their price target on Acelyrin from $11.00 to $13.00 and gave the stock an “equal weight” rating in a research report on Thursday, March 21st. HC Wainwright reiterated a “buy” rating and set a $28.00 target price on shares of Acelyrin in a research report on Monday, April 1st. Three research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $23.67.

Acelyrin Company Profile

Acelyrin, Inc, a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis.